iRadimed
IRMD
29 hedge funds and large institutions have $14M invested in iRadimed in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 12 reducing their positions, and 10 closing their positions.
9% more capital invested
Capital invested by funds: $12.9M → $14M (+$1.11M)
0.17% less ownership
Funds ownership: 13.97% → 13.79% (-0.17%)
17% less funds holding
Funds holding: 35 → 29 (-6)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
75% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 12
Top Buyers
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.07M |
| 2 |
Renaissance Technologies
New York
|
+$151K |
| 3 |
Morgan Stanley
New York
|
+$107K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$20.1K |
| 5 |
Neuberger Berman Group
New York
|
+$19K |
Top Sellers
IRMD Hedge Fund Activity: Q3 2017 in Review
29 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in iRadimed (IRMD) for Q3 2017, worth a combined $14M — up 8.6% from $12.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IRMD and 4 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 3 added.
The largest buyer was Ameriprise, adding an estimated $1.07M. The largest seller was AQR Capital Management, cutting an estimated $505K.
- 29 institutional investors held iRadimed (IRMD) as of Q3 2017, down from 35 in Q2 2017.
- Funds reported $14M of iRadimed stock for Q3 2017, up 8.6% quarter-over-quarter.
- 4 funds opened new iRadimed positions in Q3 2017 and 10 closed out, a net change of -6 holders.
- The largest iRadimed buyer in Q3 2017 was Ameriprise, an estimated $1.07M added.
- The largest iRadimed seller in Q3 2017 was AQR Capital Management, an estimated $505K sold.
Based on aggregated 13F filings for Q3 2017.